Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
03 mars 2022 07h00 HE
|
Fulcrum Therapeutics, Inc.
Reachable Workspace (RWS) primary endpoint based on discussions with FDA and EU regulatory agencies Trial expected to begin in 2Q 2022Potential first-to-market therapy for FSHDFulcrum to host virtual...
Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET
24 févr. 2022 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 févr. 2022 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases
10 janv. 2022 07h00 HE
|
Fulcrum Therapeutics, Inc.
First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; Initial data expected in 2Q 2022 Submitted IND for FTX-6058 to support initiation of Phase 1b trial in select...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 janv. 2022 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference
06 janv. 2022 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer
04 janv. 2022 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
06 déc. 2021 07h00 HE
|
Fulcrum Therapeutics, Inc.
Achieved mean 5.6-fold HBG mRNA induction at 20mg and mean 6.2-fold at 30mg after 14 days of once-daily dosing, further supporting potential of FTX-6058 to provide a functional cure Continues to be...
Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors
17 nov. 2021 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...